Pharmacotherapy Considerations in Hospitalized Patients With COVID-19 Pneumonia

us-pharmMark Malesker, PharmD, FCCP, FCCP, FCCM, FASHP, BCPS, professor of Pharmacy Practice and Medicine, was published in U.S Pharmacist, along with fellow of  Pulmonary and Critical Care Medicine, William Pruett, MD, and Lee Morrow, MD, MSc, FCP, FCCP, FCCM, ATSF, professor of Medicine in the School of Medicine, “Pharmacotherapy Considerations in Hospitalized Patients With COVID-19 Pneumonia.”

The role of the clinical pharmacist has expanded during the coronavirus disease 2019 (COVID-19) crisis. Pharmacists caring for hospitalized patients with pneumonia must simultaneously provide other team members with updated, COVID-19–specific best practices and ensure consistent application of evidence-based ICU practices, with responsibilities including optimizing medication shortages and keeping current with rapidly changing clinical information. It is also important for pharmacists to keep abreast of the unique pharmacotherapy challenges posed by COVID-19 pneumonia, understand the need for glycemic control and the controversial nature of anticoagulation, and be conversant with the medications used in mechanical ventilation. Objective data on COVID-19 therapy are lacking, and a definitive treatment algorithm will remain elusive so long as disagreement abounds.

The article will be available in the July/August 2020 edition here.